Ka Subject Expert Committee (SEC) ka Central Drugs Standards Control Organisation (CDSCO) ka ri India da tyrwa ko yei mynjur yong ka heiyatoh wa i paan bor yow yoh yei mynjur smat (Accelerated Approval Process) wa paan daka M/s Serum Institute of India waka M/s Bharat Biotech International Ltd kamjooh yow leh yaka Phase-III Trials ka M/s Cadila Healthcare Ltd.
Ka Subject Expert Committee ka CDSCO da chong yachem ko ynnin ka 1 tarik wa ynne ka 2 tarik wei da e bor ko ya kini ha wah yow chong pyrkhat da u Drugs Controller General of India yow e yei mynjur wa khaddooh.
Ka CDSCO da mynjur ko yei pynemkaam jhan donhi (Restricted Emergency use of Vaccine), deiwa booh ya ki kyndon neibynta ka M/s Serum Institute of India, Pune.
Ka CDSCO da mynjur ko leh yei pynemkaam ha ki por wa jhan deiwa husiar bha hapoh ka Trial Mode namo deiwa pyrchang hi eh hawa yatoh wa i yada na u khñiang thymme wa mih na u COVID-19 da ka M/s Bharat Biotech International Ltd., Hyderabad.
Da e bor leh wow leh yaka Phase-III Clinical Trial Protocol da ka M/s Cadila Healthcare Ltd, Ahmedabad.
